Arcturus Capex To Depreciation vs Book Value Per Share Analysis

ARCT Stock

USD 21.73 0.16 0.74%

Arcturus Therapeutics financial indicator trend analysis is way more than just evaluating Arcturus Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arcturus Therapeutics is a good investment. Please check the relationship between Arcturus Therapeutics Capex To Depreciation and its Book Value Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcturus Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private.

Capex To Depreciation vs Book Value Per Share

Capex To Depreciation vs Book Value Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arcturus Therapeutics Capex To Depreciation account and Book Value Per Share. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Arcturus Therapeutics' Capex To Depreciation and Book Value Per Share is -0.01. Overlapping area represents the amount of variation of Capex To Depreciation that can explain the historical movement of Book Value Per Share in the same time period over historical financial statements of Arcturus Therapeutics Holdings, assuming nothing else is changed. The correlation between historical values of Arcturus Therapeutics' Capex To Depreciation and Book Value Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Depreciation of Arcturus Therapeutics Holdings are associated (or correlated) with its Book Value Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Book Value Per Share has no effect on the direction of Capex To Depreciation i.e., Arcturus Therapeutics' Capex To Depreciation and Book Value Per Share go up and down completely randomly.

Correlation Coefficient

-0.01

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Most indicators from Arcturus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arcturus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcturus Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private.

At this time, Arcturus Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 236 M in 2025, despite the fact that Tax Provision is likely to grow to (3.8 K).

	2022	2023	2024	2025 (projected)
Reconciled Depreciation	1.5M	2.7M	3.5M	3.7M
Interest Income	2.6M	12.3M	15.2M	16.0M

Reconciled Depreciation Interest Income

Arcturus Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Short Term Debt	Net Tangible Assets	Other Assets	Inventory
Total Assets		0.81	0.91	0.98	0.74	-0.97	-0.79	0.89	0.98	0.72	0.49	0.98	0.48	-0.25	0.89	0.48	0.9	0.91	0.7	1.0	-0.25	0.78	0.59	0.9	0.87	-0.63
Other Current Liab	0.81		0.76	0.76	0.85	-0.8	-0.95	0.74	0.76	0.82	0.82	0.75	0.48	-0.15	0.97	0.82	0.96	0.79	0.88	0.8	-0.13	0.66	0.38	0.84	0.76	-0.77
Total Current Liabilities	0.91	0.76		0.81	0.8	-0.83	-0.82	0.8	0.89	0.77	0.5	0.88	0.43	-0.22	0.88	0.43	0.84	0.99	0.73	0.9	-0.22	0.95	0.81	0.73	0.65	-0.69
Total Stockholder Equity	0.98	0.76	0.81		0.67	-0.97	-0.72	0.86	0.96	0.66	0.43	0.97	0.43	-0.25	0.82	0.45	0.86	0.81	0.63	0.98	-0.25	0.66	0.48	0.93	0.93	-0.56
Property Plant And Equipment Net	0.74	0.85	0.8	0.67		-0.66	-0.91	0.55	0.66	0.96	0.64	0.65	0.56	-0.26	0.88	0.81	0.88	0.8	0.99	0.71	-0.23	0.73	0.6	0.69	0.57	-0.97
Net Debt	-0.97	-0.8	-0.83	-0.97	-0.66		0.73	-0.91	-0.99	-0.62	-0.46	-0.99	-0.36	0.26	-0.86	-0.42	-0.88	-0.84	-0.62	-0.98	0.25	-0.73	-0.52	-0.95	-0.95	0.52
Retained Earnings	-0.79	-0.95	-0.82	-0.72	-0.91	0.73		-0.68	-0.71	-0.89	-0.83	-0.71	-0.48	0.26	-0.94	-0.82	-0.95	-0.82	-0.92	-0.77	0.24	-0.73	-0.5	-0.77	-0.65	0.85
Accounts Payable	0.89	0.74	0.8	0.86	0.55	-0.91	-0.68		0.92	0.49	0.42	0.92	0.25	-0.18	0.83	0.31	0.77	0.82	0.51	0.9	-0.18	0.73	0.48	0.8	0.83	-0.39
Cash	0.98	0.76	0.89	0.96	0.66	-0.99	-0.71	0.92		0.62	0.42	1.0	0.36	-0.26	0.85	0.35	0.85	0.89	0.6	0.99	-0.26	0.79	0.61	0.9	0.9	-0.52
Non Current Assets Total	0.72	0.82	0.77	0.66	0.96	-0.62	-0.89	0.49	0.62		0.62	0.62	0.53	-0.24	0.84	0.79	0.87	0.76	0.96	0.68	-0.22	0.7	0.58	0.68	0.54	-0.94
Non Currrent Assets Other	0.49	0.82	0.5	0.43	0.64	-0.46	-0.83	0.42	0.42	0.62		0.4	0.47	-0.27	0.72	0.84	0.75	0.54	0.71	0.48	-0.24	0.39	0.08	0.58	0.44	-0.6
Cash And Short Term Investments	0.98	0.75	0.88	0.97	0.65	-0.99	-0.71	0.92	1.0	0.62	0.4		0.35	-0.24	0.84	0.35	0.85	0.88	0.59	0.99	-0.24	0.78	0.61	0.9	0.9	-0.51
Net Receivables	0.48	0.48	0.43	0.43	0.56	-0.36	-0.48	0.25	0.36	0.53	0.47	0.35		-0.06	0.48	0.6	0.46	0.51	0.57	0.46	-0.06	0.21	0.02	0.32	0.27	-0.57
Common Stock Total Equity	-0.25	-0.15	-0.22	-0.25	-0.26	0.26	0.26	-0.18	-0.26	-0.24	-0.27	-0.24	-0.06		-0.21	-0.19	-0.28	-0.21	-0.25	-0.25	1.0	-0.18	-0.17	-0.34	-0.27	0.3
Common Stock Shares Outstanding	0.89	0.97	0.88	0.82	0.88	-0.86	-0.94	0.83	0.85	0.84	0.72	0.84	0.48	-0.21		0.71	0.97	0.9	0.87	0.88	-0.19	0.81	0.55	0.85	0.78	-0.77
Other Current Assets	0.48	0.82	0.43	0.45	0.81	-0.42	-0.82	0.31	0.35	0.79	0.84	0.35	0.6	-0.19	0.71		0.76	0.46	0.89	0.45	-0.16	0.28	0.05	0.58	0.45	-0.83
Other Stockholder Equity	0.9	0.96	0.84	0.86	0.88	-0.88	-0.95	0.77	0.85	0.87	0.75	0.85	0.46	-0.28	0.97	0.76		0.85	0.88	0.89	-0.26	0.74	0.51	0.92	0.83	-0.79
Total Liab	0.91	0.79	0.99	0.81	0.8	-0.84	-0.82	0.82	0.89	0.76	0.54	0.88	0.51	-0.21	0.9	0.46	0.85		0.74	0.9	-0.21	0.92	0.73	0.72	0.65	-0.67
Property Plant And Equipment Gross	0.7	0.88	0.73	0.63	0.99	-0.62	-0.92	0.51	0.6	0.96	0.71	0.59	0.57	-0.25	0.87	0.89	0.88	0.74		0.67	-0.23	0.64	0.49	0.69	0.57	-0.97
Total Current Assets	1.0	0.8	0.9	0.98	0.71	-0.98	-0.77	0.9	0.99	0.68	0.48	0.99	0.46	-0.25	0.88	0.45	0.89	0.9	0.67		-0.25	0.77	0.57	0.91	0.89	-0.59
Common Stock	-0.25	-0.13	-0.22	-0.25	-0.23	0.25	0.24	-0.18	-0.26	-0.22	-0.24	-0.24	-0.06	1.0	-0.19	-0.16	-0.26	-0.21	-0.23	-0.25		-0.17	-0.17	-0.32	-0.25	0.27
Short Long Term Debt Total	0.78	0.66	0.95	0.66	0.73	-0.73	-0.73	0.73	0.79	0.7	0.39	0.78	0.21	-0.18	0.81	0.28	0.74	0.92	0.64	0.77	-0.17		0.91	0.61	0.52	-0.59
Short Term Debt	0.59	0.38	0.81	0.48	0.6	-0.52	-0.5	0.48	0.61	0.58	0.08	0.61	0.02	-0.17	0.55	0.05	0.51	0.73	0.49	0.57	-0.17	0.91		0.4	0.32	-0.52
Net Tangible Assets	0.9	0.84	0.73	0.93	0.69	-0.95	-0.77	0.8	0.9	0.68	0.58	0.9	0.32	-0.34	0.85	0.58	0.92	0.72	0.69	0.91	-0.32	0.61	0.4		0.97	-0.59
Other Assets	0.87	0.76	0.65	0.93	0.57	-0.95	-0.65	0.83	0.9	0.54	0.44	0.9	0.27	-0.27	0.78	0.45	0.83	0.65	0.57	0.89	-0.25	0.52	0.32	0.97		-0.46
Inventory	-0.63	-0.77	-0.69	-0.56	-0.97	0.52	0.85	-0.39	-0.52	-0.94	-0.6	-0.51	-0.57	0.3	-0.77	-0.83	-0.79	-0.67	-0.97	-0.59	0.27	-0.59	-0.52	-0.59	-0.46

Click cells to compare fundamentals

Arcturus Therapeutics Account Relationship Matchups

Arcturus Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	476.5M	392.8M	450.4M	429.4M	344.1M	194.0M
Other Current Liab	17.8M	22.0M	17.6M	24.4M	29.3M	30.7M
Total Current Liabilities	49.5M	99.5M	127.0M	82.0M	65.5M	37.7M
Total Stockholder Equity	396.6M	228.2M	270.3M	278.5M	241.0M	131.5M
Property Plant And Equipment Net	8.6M	11.3M	45.0M	40.9M	36.2M	38.0M
Net Debt	(445.0M)	(302.9M)	(301.0M)	(261.8M)	(208.5M)	(198.1M)
Retained Earnings	(143.8M)	(347.5M)	(338.1M)	(367.9M)	(448.8M)	(426.4M)
Accounts Payable	10.8M	10.1M	7.4M	5.3M	7.2M	4.3M
Cash	462.9M	370.5M	391.9M	292.0M	237.0M	151.7M
Non Current Assets Total	8.7M	13.9M	47.1M	42.8M	38.1M	40.0M
Cash And Short Term Investments	462.9M	370.5M	391.9M	292.0M	237.0M	163.8M
Net Receivables	2.1M	3.4M	2.8M	32.1M	4.0M	4.4M
Common Stock Shares Outstanding	20.3M	26.3M	27.1M	26.6M	27M	28.4M
Liabilities And Stockholders Equity	476.5M	392.8M	450.4M	429.4M	344.1M	194.0M
Other Current Assets	2.8M	5.1M	8.7M	62.5M	65.0M	68.2M
Other Stockholder Equity	540.3M	575.7M	608.4M	646.4M	689.8M	724.2M
Total Liab	79.9M	164.6M	180.1M	150.9M	103.1M	62.5M
Property Plant And Equipment Gross	8.6M	11.3M	45.0M	49.7M	48.0M	50.4M
Total Current Assets	467.8M	379.0M	403.3M	386.6M	306.0M	179.7M
Common Stock	214K	15K	26K	27K	24.3K	46.2K
Short Long Term Debt Total	20.8M	69.1M	94.8M	30.2M	28.6M	33.5M
Short Term Debt	2.9M	24.0M	64.5M	4.3M	7.1M	6.7M
Net Tangible Assets	13.6M	25.8M	396.6M	228.2M	262.4M	275.6M
Property Plant Equipment	7.5M	3.4M	11.3M	45.0M	51.7M	54.3M
Capital Surpluse	58.3M	97.4M	540.3M	575.7M	662.0M	695.1M
Other Liab	15.2M	12.5M	19.9M	22.9M	26.3M	14.0M
Current Deferred Revenue	18.1M	43.5M	36.1M	47.3M	21.9M	23.5M
Non Current Liabilities Total	30.4M	65.1M	53.1M	68.9M	37.6M	38.9M
Net Invested Capital	411.6M	291.3M	331.0M	278.5M	241.0M	227.1M
Net Working Capital	418.3M	279.4M	276.3M	304.6M	240.5M	225.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arcturus Stock Analysis

When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC